Back to results
US 6,632,945 B2Granted
Inhibitors of P38
AssigneeVertex Pharmaceuticals Incorporated
InventorsFrancesco Salituro, Vincent Galullo, Steven Bellon, Guy Bemis, John Cochran
Life of this patent
Estimating the term…
Abstract
The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
Claims24
A compound of the formula:
- wherein each of Q1 and Q2 is independently selected from a phenyl, a 5-6 membered aromatic heterocyclic ring system, or a 8-10 membered bicyclic ring system selected from the group consisting of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring;
- the rings that make up Q1 are substituted with 1 to 4 substituents, each of which is independently selected from halo;
- C1-C3 alkyl optionally substituted with NR′2, OR′, CO2R′ or CONR′2;
- O—(C1-C3)-alkyl optionally substituted with NR′2, OR′, CO2R′ or CONR′2;
- NR′2;
- OCF3;
- CF3;
- NO2;
- CO2R′;
- CONHR′;
- SR′;
- S(O2)N(R′)2;
- SCF3;
- CN;
- N(R′)C(O)R4;
- N(R′)C(O)OR4;
- N(R′)C(O)C(O)R4;
- N(R′)S(O2)R4;
- N(R′)R4;
- N(R4)2;
- OR4;
- OC(O)R4;
- OP(O)3H2;
- or N=CH—N(R′)2;
- the rings that make up Q2 are optionally substituted with up to 4 substituents, each of which is independently selected from halo;
- C1-C3 straight or branched alkyl optionally substituted with NR′2, OR′, CO2R′, S(O2)N(R′)2, N=CH—N(R′)2, R3, or CONR′2;
- O—(C1-C3)-alkyl optionally substituted with NR′2, OR′, CO2R′, S(O2)N(R′)2, N=CH—N(R′)2, R3, or CONR′2;
- NR′2;
- OCF3;
- CF3;
- NO2;
- CO2R′;
- CONHR′;
- R3;
- OR3;
- NHR3;
- SR3;
- C(O)R3;
- C(O)N(R′)R3;
- C(O)OR3;
- SR′;
- S(O2)N(R′)2;
- SCF3;
- N=CH—N(R′)2;
- or CN;
- Q2′ is selected from phenyl or a 5-6 member aromatic heterocyclic ring optionally substituted with 1-3 substituents, each of which is independently selected from halogen;
- C1-C3 alkyl optionally substituted with NR′2, OR′, CO2R′, CONR′2, or O—P(O3)H2;
- O—(C2-C3)-alkyl optionally substituted with NR′2, OR′, CO2R′, CONR′2, or OP(O3)H2;
- OCF3;
- CF3;
- OR4;
- O—CO2R4;
- O—P(O3)H2;
- CO2R′;
- CONHR′;
- SR′;
- S(O2)N(R′)2;
- SCF3;
- CN;
- N(R′)C(O)R4;
- N(R′)C(O)OR4;
- N(R′)C(O)C(O)R4;
- N(R′)S(O2)R4;
- N(R′)R4;
- N(R4)2;
- OR4;
- OC(O)R4;
- OP(O)3H2;
- or N=CH—N(R′)2;
- provided that Q2′ is not phenyl optionally substituted 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl;
- R′ is selected from hydrogen;
- (C1-C3)-alkyl;
- (C2-C3)-alkenyl or alkynyl;
- phenyl or phenyl substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl;
- or a 5-6 membered heterocyclic ring system optionally substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl;
- R3 is selected from 5-8 membered aromatic or non-aromatic carbocyclic or heterocyclic ring systems each optionally substituted with R′, R4, —C(O)R′, —C(O)R4, —C(O)OR4 or -J;
- or an 8-10 membered bicyclic ring system selected from the group consisting of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring each optionally substituted with R′, R4, —C(O)R′, —C(O)R4, —C(O)OR4 or -J;
- R4 is (C1-C4)-straight or branched alkyl optionally substituted with N(R′)2, OR′, CO2R′, CON(R′)2, or SO2N(R2)2;
- or a 5-6 membered carbocyclic or heterocyclic ring system optionally substituted with N(R′)2, OR′, CO2R′, CON(R′)2, or SO2N(R2)2;
- R5 is selected from hydrogen;
- (C1-C3)-alkyl optionally substituted with R3;
- (C2-C3)-alkenyl or alkynyl each optionally substituted with R3;
- phenyl or phenyl substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl;
- or a 5-6 membered heterocyclic ring system optionally substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl;
- W is selected from hydrogen;
- N(R2)SO2—N(R2)2;
- N(R2)SO2—N(R2)(R3);
- N(R2)C(O)—OR2;
- N(R2)C(O)—N(R2)2;
- N(R2)C(O)—N(R2)(R3);
- N(R2)C(O)—R2;
- N(R2)2;
- C(O)—R2;
- CH(OH)—R2;
- C(O)—N(R2)2;
- C(O)—OR2;
- J;
- or (C1-C4) straight or branched alkyl optionally substituted with N(R′)2, OR′, CO2R′, CON(R′)2, R3, SO2N(R2)2, OC(O)R2, OC(O)R′, OC(O)N(R2)2, —N(R4)(R5), —C(O)N(R5)(R2), —C(O)R5, —N(R2)C(O)N(R2)(R5), —NC(O)OR5, —OC(O)N(R2)(R5), or -J;
- a 5-6 membered carbocyclic or heterocyclic ring system optionally substituted with N(R′)2, OR′, CO2R′, CON(R′)2, or SO2N(R2)2;
- or a 8-10 membered carbocyclic or heterocyclic ring system optionally substituted with N(R′)2, OR′, CO2R′, CON(R′)2, or SO2N(R2)2;
- provided that, unless U is W, W is not an R3 substituted C1 alkyl;
- W′ is selected from N(R2)—SO2—Q2;
- N(R2)—CO2—Q2;
- N(R2)—C(O)—Q2;
- N(R2)(Q2);
- C(O)—Q2;
- CO2—Q2;
- C(O)N(R2)(Q2);
- C(R2)2Q2;
- each R is independently selected from hydrogen, —R2, —N(R2)2, —OR2, SR2, —C(O)—N(R2)2, —S(O2)—N(R2)2, —C(O)—OR2 or —C(O)R2 wherein two adjacent R are optionally bound to one another and, together with each Y to which they are respectively bound, form a 4-8 membered carbocyclic or heterocyclic ring;
- R2 is selected from hydrogen, (C1-C3)-alkyl, or (C1-C3)-alkenyl;
- wherein each (C1-C3)-alkyl or (C1-C3)-alkenyl is optionally substituted with —N(R′)2, —OR′, SR′, —C(O)—N(R′)2, —S(O2)—N(R′)2, —C(O)—OR′, —NSO2R4, —NSO2R3, —C(O)N(R′)(R3), —NC(O)R4, —N(R′)(R3), —N(R′)(R4), —C(O)R3, —C(O)N(R′)(R4), —N(R4)2, —C(O)N═C(NH)2 or R3;
- Y is C;
- Z is CH, N, C(OCH3), C(CH3), C(NH2), C(OH) or C(F);
- U is selected from R or W;
- V is selected from —C(O)NH2, —P(O)(NH2)2, or —SO2NH2;
- J is a (C1-C4) straight chain or branched alkyl substituted with 1-3 substituents selected from D, —T—C(O)R′, or —OPO3H2;
- D is selected from
- T is O or NH;
- and
- G is NH2 or OH;
- provided that in compounds of formula (Ia), when W is hydrogen, Z is CU or N, and V is —C(O)NH2, then U is not hydrogen;
- and
- in compounds of formula (Ia), when W is hydrogen;
- Z is CH or N;
- V is —C(O)NH2;
- and U is —R2, —N(R2)2, —OR2, —SR2, —C(O)—N(R2)2, —S(O2)—N(R2)2, —C(O)—OR2 or —C(O)R2;
- then each of these R2 is not hydrogen, (C1-C3)-alkyl, or (C2-C3)-alkenyl, or (C1-C3)-alkyl or (C2-C3)-alkenyl substituted with —N(R′)2, —OR′, —SR′, —C(O)—N(R′)2, —S(O2)—N(R′)2, —C(O)—OR′, or an unsubstituted 5-6 membered aromatic carbocyclic or heterocyclic ring system.
125 more elements
Dependencies are inferred from the claim text.